Research programme: parasitic disease therapeutics - MabVax/Swiss Tropical and Public Health Institute

Drug Profile

Research programme: parasitic disease therapeutics - MabVax/Swiss Tropical and Public Health Institute

Latest Information Update: 10 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Telik
  • Developer MabVax Therapeutics; Swiss Tropical and Public Health Institute
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Parasitic infections

Most Recent Events

  • 10 Oct 2014 No development reported for Parasitic infections in USA and Switzerland (unspecified route)
  • 02 Nov 2010 Telik receives Qualifying Therapeutic Discovery Project grant under the Patient Protection and Affordable Care Act of 2010 (PPACA)
  • 31 Oct 2008 Early research in Parasitic infections in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top